Company Overview - LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company focused on developing and commercializing the first and only aceclidine-based eye drop aimed at improving near vision in individuals with presbyopia [3] - The product candidate, LNZ100, is a preservative-free, single-use, once-daily eye drop containing aceclidine [3] - Presbyopia affects an estimated 1.8 billion people globally and 128 million people in the United States [3] Upcoming Events - Company management will participate in a fireside chat and one-on-one meetings at the BofA Securities 2025 Health Care Conference from May 13-15, 2025, in Las Vegas, NV [1] - The presentation is scheduled for May 13, 2025, at 9:20 am PDT / 12:20 pm EDT [2] - A live audio webcast of the conference presentation will be available on the LENZ Therapeutics website, with a replay accessible for 12 months post-event [2] Regulatory Milestones - The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100 [3] - The company is committed to commercializing an ideal pharmaceutical solution for presbyopia that enhances vision for "all eyes, all day" [3]